Clinical Trials · NCT00747786
Non Interventional Post Marketing Programme in Neuroendocrine Tumours
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 40
- Start date
- Dec 2008
- Locations
- 5 sites, United Kingdom
- Primary endpoint
- safety and local tolerability of Somatuline Autogel when administered by patients or their partners or from a healthcare professional